Equities analysts expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings per share of ($0.49) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Enanta Pharmaceuticals’ earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.59). Enanta Pharmaceuticals posted earnings of ($0.06) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 716.7%. The business is scheduled to report its next quarterly earnings report on Monday, August 14th.
On average, analysts expect that Enanta Pharmaceuticals will report full-year earnings of $0.02 per share for the current financial year, with EPS estimates ranging from $0.01 to $0.03. For the next year, analysts anticipate that the business will report earnings of ($0.10) per share, with EPS estimates ranging from ($0.42) to $0.21. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($0.28) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.10. The firm had revenue of $9 million for the quarter, compared to analyst estimates of $9.19 million. Enanta Pharmaceuticals had a negative return on equity of 4.94% and a negative net margin of 28.68%. The business’s quarterly revenue was down 30.8% compared to the same quarter last year. During the same period last year, the company earned ($0.09) EPS.
ENTA has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. BidaskClub cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. JMP Securities raised shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price objective on the stock in a research report on Tuesday. Finally, ValuEngine raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $30.75.
Several large investors have recently bought and sold shares of the company. State Street Corp raised its stake in Enanta Pharmaceuticals by 71.5% in the fourth quarter. State Street Corp now owns 568,238 shares of the biotechnology company’s stock worth $19,036,000 after buying an additional 236,871 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Enanta Pharmaceuticals by 129.7% in the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock worth $12,723,000 after buying an additional 233,265 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in Enanta Pharmaceuticals by 50.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 356,000 shares of the biotechnology company’s stock worth $10,965,000 after buying an additional 120,000 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Enanta Pharmaceuticals during the first quarter worth $1,731,000. Finally, Vanguard Group Inc. raised its stake in Enanta Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 792,165 shares of the biotechnology company’s stock worth $24,399,000 after buying an additional 53,007 shares in the last quarter. Institutional investors own 67.32% of the company’s stock.
Enanta Pharmaceuticals (NASDAQ ENTA) opened at 36.47 on Friday. The company’s market capitalization is $695.96 million. The firm has a 50-day moving average price of $32.65 and a 200-day moving average price of $31.68. Enanta Pharmaceuticals has a 12 month low of $20.79 and a 12 month high of $38.40.
ILLEGAL ACTIVITY WARNING: This news story was first reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/zacks-brokerages-anticipate-enanta-pharmaceuticals-inc-nasdaqenta-will-post-earnings-of-0-49-per-share-updated-updated-updated/1196668.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.